| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $943K | -8.0% | -32.6% |
| SG&A Expense | $886K | -62.2% | +169.3% |
| Operating Income | -$2.3M | +42.0% | +25.7% |
| Net Income | -$2.3M | +36.7% | +38.0% |
| EPS (Basic) | -$1.05 | +68.1% | +34.0% |
| EPS (Diluted) | -$1.05 | +68.1% | +34.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $2.1M | -56.5% | +1237.1% |
| Current Assets | $3.3M | -37.1% | +803.8% |
| Total Assets | $3.5M | -35.6% | +426.0% |
| Current Liabilities | $2.0M | +16.1% | +18.4% |
| Total Liabilities | $2.1M | +13.2% | +8.0% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$8.5M | — | — |
| Investing Cash Flow | $2.9M | — | — |
| Financing Cash Flow | $8.7M | — | — |
| $1.4M |
| -61.3% |
| +206.0% |